RASP (Actavia Life Sciences) Debt-to-EBITDA : -1.07 (As of Mar. 2024)

What is Actavia Life Sciences Debt-to-EBITDA?

Actavia Life Sciences RASP -87.50% Debt-to-EBITDA is -1.07 as of Mar. 2024.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Actavia Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.30 Mil. Actavia Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Actavia Life Sciences's annualized EBITDA for the quarter that ended in Mar. 2024 was $-0.28 Mil. Actavia Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -1.07.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Actavia Life Sciences's Debt-to-EBITDA or its related term are showing as below:

RASP's Debt-to-EBITDA is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.14
* Ranked among companies with meaningful Debt-to-EBITDA only.

Actavia Life Sciences (OTCPK:RASP) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Actavia Life Sciences Debt-to-EBITDA Related Terms

Actavia Life Sciences Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Actavia Life Sciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actavia Life Sciences Debt-to-EBITDA Chart

Actavia Life Sciences Annual Data

Trend

Jun14

Jun15

Jun16

Mar17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.29

-0.10

-1.90

0.87

-0.05

Actavia Life Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.01	-0.54	-1.08	-0.46	-1.07

RASP vs BWV, FNCH, CWBR: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Actavia Life Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actavia Life Sciences Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actavia Life Sciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Actavia Life Sciences's Debt-to-EBITDA falls into.

Save Embed

Actavia Life Sciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Actavia Life Sciences's Debt-to-EBITDA for the fiscal year that ended in Sep. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.211	+	0)	/	-4.23
	=	-0.05

Actavia Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.304	+	0)	/	-0.284
	=	-1.07

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →

What does a Debt-to-EBITDA of -1.07 mean?

Actavia Life Sciences (RASP) has a Debt-to-EBITDA of -1.07 as of Mar. 2024. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Actavia Life Sciences.

Is Actavia Life Sciences' Debt-to-EBITDA too high?

Actavia Life Sciences' current Debt-to-EBITDA is -1.07.

How does Actavia Life Sciences' Debt-to-EBITDA compare to BWV and FNCH?

Actavia Life Sciences' Debt-to-EBITDA of -1.07 can be compared against companies in the Biotechnology industry. The industry median Debt-to-EBITDA is 1.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Debt-to-EBITDA for a Biotechnology company?

The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Debt-to-EBITDA mean?

A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Actavia Life Sciences. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Actavia Life Sciences's current Debt-to-EBITDA is -1.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Actavia Life Sciences stock overvalued right now?

Actavia Life Sciences (RASP) has a current Debt-to-EBITDA of -1.07. The current Debt-to-EBITDA is -1.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Debt-to-EBITDA calculated?

Debt-to-EBITDA is calculated from a company's financial statements. For Actavia Life Sciences (RASP), the current Debt-to-EBITDA is -1.07 as of Mar. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actavia Life Sciences Business Description

Industry Healthcare Biotechnology

Comparable Companies BWV FNCH CWBR NRSN EMMA CELZ MNPR AMTI PYPD CYCN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Address 5 Penn Plaza, No.1954, 19th Floor, New York, NY, USA, 10001

Website https://www.rasna.com

Actavia Life Sciences Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.